News from mirati therapeutics, inc

Jun 30, 2014, 16:01 ET

Mirati Therapeutics Added to Russell 2000 Index

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual...

Jun 17, 2014, 08:00 ET

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan...

Jun 12, 2014, 08:00 ET

Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference...

May 22, 2014, 08:00 ET

Mirati Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the Jefferies 2014 Global Healthcare Conference on...

May 15, 2014, 16:01 ET

Mirati Therapeutics Reports First Quarter 2014 Financial Results and Provides Business Update

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2014 and provided...

Mar 20, 2014, 08:00 ET

William R. Ringo Joins Mirati Board of Directors

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of...

Mar 17, 2014, 16:01 ET

Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and year ended December 31, 2013 and...

Feb 05, 2014, 08:00 ET

Mirati Therapeutics to Present at the 2014 Leerink Global Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on...

Dec 09, 2013, 10:10 ET

Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting...

Dec 02, 2013, 08:00 ET

Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference...

Nov 22, 2013, 08:00 ET

Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

 Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference...

Nov 12, 2013, 08:00 ET

Mirati Therapeutics Reports Third Quarter 2013 Financial Results

Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30,...

Nov 08, 2013, 08:00 ET

Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting

 Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in...

Oct 23, 2013, 20:13 ET

Mirati Therapeutics Prices Public Offering Of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at...

Oct 16, 2013, 16:15 ET

Mirati Therapeutics Announces Public Offering Of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it is offering to sell 3,000,000 shares of its common stock in an underwritten public...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer